# Eli Lilly and Company net income entity: /record/eli-lilly.md predicate: net_income page: /record/eli-lilly/net_income as_of: 2026-11-08 cite: AsOf. "Eli Lilly and Company quarterly net income: 6,451,000,000 United States dollar", as of 2026-09-30. Claim clm_9D57FD94603E, https://asof.is/claim/clm_9D57FD94603E, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947826000108/0000059478-26-000108-index.htm. As of November 8, 2026, the latest net income figure on the AsOf record for Eli Lilly and Company is $6.45 billion for the quarter ended September 30, 2026, from a primary source (sec.gov). Eli Lilly and Company's latest full-year net income is $20.64 billion, dated December 31, 2025, from a primary source (sec.gov); the two periods are kept apart, never compared. 19 claims on Eli Lilly and Company's net income, 1 open and 18 superseded, each dated and sourced; a replaced value is closed with an end date, never deleted. ## Latest net income The newest figure for a shorter period, the quarter ended September 30, 2026: a quarterly_net_income claim, kept apart from the full-year series. - [Eli Lilly and Company](/record/eli-lilly.md) | quarterly_net_income | 6,451,000,000 United States dollar | valid 2026-09-30 to present | conf 0.95 | valid | [clm_9D57FD94603E](/claim/clm_9D57FD94603E.md) sources: https://www.sec.gov/Archives/edgar/data/59478/000005947826000108/0000059478-26-000108-index.htm ## Latest full-year net income What the record asserts on 2026-11-08. - [Eli Lilly and Company](/record/eli-lilly.md) | net_income | 20,640,000,000 United States dollar | valid 2025-12-31 to present | conf 0.95 | valid | [clm_DBEC55E24C06](/claim/clm_DBEC55E24C06.md) sources: https://www.sec.gov/Archives/edgar/data/59478/000005947826000013/0000059478-26-000013-index.htm ## Every dated value One claim per line, oldest first. Superseded claims stay visible. - [Eli Lilly and Company](/record/eli-lilly.md) | net_income | 2,953,000,000 United States dollar | valid 2007-12-31 to 2008-12-31 | conf 0.95 | superseded | superseded_by [clm_A9151DC389AD](/claim/clm_A9151DC389AD.md) | [clm_F48D85F877C4](/claim/clm_F48D85F877C4.md) sources: https://www.sec.gov/Archives/edgar/data/59478/000095012310014958/0000950123-10-014958-index.htm - [Eli Lilly and Company](/record/eli-lilly.md) | net_income | -2,071,900,000 United States dollar | valid 2008-12-31 to 2009-12-31 | conf 0.95 | superseded | superseded_by [clm_5EE235488841](/claim/clm_5EE235488841.md) | [clm_A9151DC389AD](/claim/clm_A9151DC389AD.md) sources: https://www.sec.gov/Archives/edgar/data/59478/000095012310014958/0000950123-10-014958-index.htm - [Eli Lilly and Company](/record/eli-lilly.md) | net_income | 4,328,800,000 United States dollar | valid 2009-12-31 to 2010-12-31 | conf 0.95 | superseded | superseded_by [clm_4BDBC4365AB7](/claim/clm_4BDBC4365AB7.md) | [clm_5EE235488841](/claim/clm_5EE235488841.md) sources: https://www.sec.gov/Archives/edgar/data/59478/000095012310014958/0000950123-10-014958-index.htm - [Eli Lilly and Company](/record/eli-lilly.md) | net_income | 5,069,500,000 United States dollar | valid 2010-12-31 to 2011-12-31 | conf 0.95 | superseded | superseded_by [clm_7E497C262CA8](/claim/clm_7E497C262CA8.md) | [clm_4BDBC4365AB7](/claim/clm_4BDBC4365AB7.md) sources: https://www.sec.gov/Archives/edgar/data/59478/000119312511041620/0001193125-11-041620-index.htm - [Eli Lilly and Company](/record/eli-lilly.md) | net_income | 4,347,700,000 United States dollar | valid 2011-12-31 to 2012-12-31 | conf 0.95 | superseded | superseded_by [clm_592E3DCB062C](/claim/clm_592E3DCB062C.md) | [clm_7E497C262CA8](/claim/clm_7E497C262CA8.md) sources: https://www.sec.gov/Archives/edgar/data/59478/000119312512078393/0001193125-12-078393-index.htm - [Eli Lilly and Company](/record/eli-lilly.md) | net_income | 4,088,600,000 United States dollar | valid 2012-12-31 to 2013-12-31 | conf 0.95 | superseded | superseded_by [clm_172E66143A90](/claim/clm_172E66143A90.md) | [clm_592E3DCB062C](/claim/clm_592E3DCB062C.md) sources: https://www.sec.gov/Archives/edgar/data/59478/000005947813000007/0000059478-13-000007-index.htm - [Eli Lilly and Company](/record/eli-lilly.md) | net_income | 4,684,800,000 United States dollar | valid 2013-12-31 to 2014-12-31 | conf 0.95 | superseded | superseded_by [clm_822B542164C0](/claim/clm_822B542164C0.md) | [clm_172E66143A90](/claim/clm_172E66143A90.md) sources: https://www.sec.gov/Archives/edgar/data/59478/000005947814000078/0000059478-14-000078-index.htm - [Eli Lilly and Company](/record/eli-lilly.md) | net_income | 2,390,500,000 United States dollar | valid 2014-12-31 to 2015-12-31 | conf 0.95 | superseded | superseded_by [clm_4EA9C0C3EB44](/claim/clm_4EA9C0C3EB44.md) | [clm_822B542164C0](/claim/clm_822B542164C0.md) sources: https://www.sec.gov/Archives/edgar/data/59478/000005947815000100/0000059478-15-000100-index.htm - [Eli Lilly and Company](/record/eli-lilly.md) | net_income | 2,408,400,000 United States dollar | valid 2015-12-31 to 2016-12-31 | conf 0.95 | superseded | superseded_by [clm_ECD98570FDF4](/claim/clm_ECD98570FDF4.md) | [clm_4EA9C0C3EB44](/claim/clm_4EA9C0C3EB44.md) sources: https://www.sec.gov/Archives/edgar/data/59478/000005947816000321/0000059478-16-000321-index.htm - [Eli Lilly and Company](/record/eli-lilly.md) | net_income | 2,737,600,000 United States dollar | valid 2016-12-31 to 2017-12-31 | conf 0.95 | superseded | superseded_by [clm_A49582D43487](/claim/clm_A49582D43487.md) | [clm_ECD98570FDF4](/claim/clm_ECD98570FDF4.md) sources: https://www.sec.gov/Archives/edgar/data/59478/000005947817000098/0000059478-17-000098-index.htm - [Eli Lilly and Company](/record/eli-lilly.md) | net_income | -204,100,000 United States dollar | valid 2017-12-31 to 2018-12-31 | conf 0.95 | superseded | superseded_by [clm_B5442530014B](/claim/clm_B5442530014B.md) | [clm_A49582D43487](/claim/clm_A49582D43487.md) sources: https://www.sec.gov/Archives/edgar/data/59478/000005947818000089/0000059478-18-000089-index.htm - [Eli Lilly and Company](/record/eli-lilly.md) | net_income | 3,232,000,000 United States dollar | valid 2018-12-31 to 2019-12-31 | conf 0.95 | superseded | superseded_by [clm_9519CD02B8A4](/claim/clm_9519CD02B8A4.md) | [clm_B5442530014B](/claim/clm_B5442530014B.md) sources: https://www.sec.gov/Archives/edgar/data/59478/000005947819000082/0000059478-19-000082-index.htm - [Eli Lilly and Company](/record/eli-lilly.md) | net_income | 8,318,400,000 United States dollar | valid 2019-12-31 to 2020-12-31 | conf 0.95 | superseded | superseded_by [clm_AABFB7142885](/claim/clm_AABFB7142885.md) | [clm_9519CD02B8A4](/claim/clm_9519CD02B8A4.md) sources: https://www.sec.gov/Archives/edgar/data/59478/000005947820000057/0000059478-20-000057-index.htm - [Eli Lilly and Company](/record/eli-lilly.md) | net_income | 6,193,700,000 United States dollar | valid 2020-12-31 to 2021-12-31 | conf 0.95 | superseded | superseded_by [clm_BE501ABAA6B4](/claim/clm_BE501ABAA6B4.md) | [clm_AABFB7142885](/claim/clm_AABFB7142885.md) sources: https://www.sec.gov/Archives/edgar/data/59478/000005947821000083/0000059478-21-000083-index.htm - [Eli Lilly and Company](/record/eli-lilly.md) | net_income | 5,581,700,000 United States dollar | valid 2021-12-31 to 2022-12-31 | conf 0.95 | superseded | superseded_by [clm_B3346D345CCB](/claim/clm_B3346D345CCB.md) | [clm_BE501ABAA6B4](/claim/clm_BE501ABAA6B4.md) sources: https://www.sec.gov/Archives/edgar/data/59478/000005947822000068/0000059478-22-000068-index.htm - [Eli Lilly and Company](/record/eli-lilly.md) | net_income | 6,244,800,000 United States dollar | valid 2022-12-31 to 2023-12-31 | conf 0.95 | superseded | superseded_by [clm_2C28B4C8BA34](/claim/clm_2C28B4C8BA34.md) | [clm_B3346D345CCB](/claim/clm_B3346D345CCB.md) sources: https://www.sec.gov/Archives/edgar/data/59478/000005947823000082/0000059478-23-000082-index.htm - [Eli Lilly and Company](/record/eli-lilly.md) | net_income | 5,240,400,000 United States dollar | valid 2023-12-31 to 2024-12-31 | conf 0.95 | superseded | superseded_by [clm_2BC21A73296C](/claim/clm_2BC21A73296C.md) | [clm_2C28B4C8BA34](/claim/clm_2C28B4C8BA34.md) sources: https://www.sec.gov/Archives/edgar/data/59478/000005947824000065/0000059478-24-000065-index.htm - [Eli Lilly and Company](/record/eli-lilly.md) | net_income | 10,590,000,000 United States dollar | valid 2024-12-31 to 2025-12-31 | conf 0.95 | superseded | superseded_by [clm_DBEC55E24C06](/claim/clm_DBEC55E24C06.md) | [clm_2BC21A73296C](/claim/clm_2BC21A73296C.md) sources: https://www.sec.gov/Archives/edgar/data/59478/000005947825000067/0000059478-25-000067-index.htm - [Eli Lilly and Company](/record/eli-lilly.md) | net_income | 20,640,000,000 United States dollar | valid 2025-12-31 to present | conf 0.95 | valid | [clm_DBEC55E24C06](/claim/clm_DBEC55E24C06.md) sources: https://www.sec.gov/Archives/edgar/data/59478/000005947826000013/0000059478-26-000013-index.htm ## What replaced what - $2.95 billion (2007-12-31 to 2008-12-31, [clm_F48D85F877C4](/claim/clm_F48D85F877C4.md)) was replaced by -$2.07 billion from 2008-12-31 ([clm_A9151DC389AD](/claim/clm_A9151DC389AD.md)) - -$2.07 billion (2008-12-31 to 2009-12-31, [clm_A9151DC389AD](/claim/clm_A9151DC389AD.md)) was replaced by $4.33 billion from 2009-12-31 ([clm_5EE235488841](/claim/clm_5EE235488841.md)) - $4.33 billion (2009-12-31 to 2010-12-31, [clm_5EE235488841](/claim/clm_5EE235488841.md)) was replaced by $5.07 billion from 2010-12-31 ([clm_4BDBC4365AB7](/claim/clm_4BDBC4365AB7.md)) - $5.07 billion (2010-12-31 to 2011-12-31, [clm_4BDBC4365AB7](/claim/clm_4BDBC4365AB7.md)) was replaced by $4.35 billion from 2011-12-31 ([clm_7E497C262CA8](/claim/clm_7E497C262CA8.md)) - $4.35 billion (2011-12-31 to 2012-12-31, [clm_7E497C262CA8](/claim/clm_7E497C262CA8.md)) was replaced by $4.09 billion from 2012-12-31 ([clm_592E3DCB062C](/claim/clm_592E3DCB062C.md)) - $4.09 billion (2012-12-31 to 2013-12-31, [clm_592E3DCB062C](/claim/clm_592E3DCB062C.md)) was replaced by $4.68 billion from 2013-12-31 ([clm_172E66143A90](/claim/clm_172E66143A90.md)) - $4.68 billion (2013-12-31 to 2014-12-31, [clm_172E66143A90](/claim/clm_172E66143A90.md)) was replaced by $2.39 billion from 2014-12-31 ([clm_822B542164C0](/claim/clm_822B542164C0.md)) - $2.39 billion (2014-12-31 to 2015-12-31, [clm_822B542164C0](/claim/clm_822B542164C0.md)) was replaced by $2.41 billion from 2015-12-31 ([clm_4EA9C0C3EB44](/claim/clm_4EA9C0C3EB44.md)) - $2.41 billion (2015-12-31 to 2016-12-31, [clm_4EA9C0C3EB44](/claim/clm_4EA9C0C3EB44.md)) was replaced by $2.74 billion from 2016-12-31 ([clm_ECD98570FDF4](/claim/clm_ECD98570FDF4.md)) - $2.74 billion (2016-12-31 to 2017-12-31, [clm_ECD98570FDF4](/claim/clm_ECD98570FDF4.md)) was replaced by -$204.1 million from 2017-12-31 ([clm_A49582D43487](/claim/clm_A49582D43487.md)) - -$204.1 million (2017-12-31 to 2018-12-31, [clm_A49582D43487](/claim/clm_A49582D43487.md)) was replaced by $3.23 billion from 2018-12-31 ([clm_B5442530014B](/claim/clm_B5442530014B.md)) - $3.23 billion (2018-12-31 to 2019-12-31, [clm_B5442530014B](/claim/clm_B5442530014B.md)) was replaced by $8.32 billion from 2019-12-31 ([clm_9519CD02B8A4](/claim/clm_9519CD02B8A4.md)) - $8.32 billion (2019-12-31 to 2020-12-31, [clm_9519CD02B8A4](/claim/clm_9519CD02B8A4.md)) was replaced by $6.19 billion from 2020-12-31 ([clm_AABFB7142885](/claim/clm_AABFB7142885.md)) - $6.19 billion (2020-12-31 to 2021-12-31, [clm_AABFB7142885](/claim/clm_AABFB7142885.md)) was replaced by $5.58 billion from 2021-12-31 ([clm_BE501ABAA6B4](/claim/clm_BE501ABAA6B4.md)) - $5.58 billion (2021-12-31 to 2022-12-31, [clm_BE501ABAA6B4](/claim/clm_BE501ABAA6B4.md)) was replaced by $6.24 billion from 2022-12-31 ([clm_B3346D345CCB](/claim/clm_B3346D345CCB.md)) - $6.24 billion (2022-12-31 to 2023-12-31, [clm_B3346D345CCB](/claim/clm_B3346D345CCB.md)) was replaced by $5.24 billion from 2023-12-31 ([clm_2C28B4C8BA34](/claim/clm_2C28B4C8BA34.md)) - $5.24 billion (2023-12-31 to 2024-12-31, [clm_2C28B4C8BA34](/claim/clm_2C28B4C8BA34.md)) was replaced by $10.59 billion from 2024-12-31 ([clm_2BC21A73296C](/claim/clm_2BC21A73296C.md)) - $10.59 billion (2024-12-31 to 2025-12-31, [clm_2BC21A73296C](/claim/clm_2BC21A73296C.md)) was replaced by $20.64 billion from 2025-12-31 ([clm_DBEC55E24C06](/claim/clm_DBEC55E24C06.md)) ## Questions this record answers ### What is Eli Lilly and Company's current net income? The latest figure on the record is $6.45 billion for the quarter ended September 30, 2026, from a primary source (sec.gov). The latest full-year figure is $20.64 billion, dated December 31, 2025, from a primary source (sec.gov). The record asserts both as of November 8, 2026. ### What was Eli Lilly and Company's net income for the quarter ended September 30, 2026? $6.45 billion for the quarter ended September 30, 2026, dated September 30, 2026, from a primary source (sec.gov) (status valid, confidence 0.95). ### When did Eli Lilly and Company's net income last change? The latest value on the record is $20.64 billion, dated December 31, 2025; before it the record holds $10.59 billion, dated December 31, 2024 and closed on December 31, 2025. ### What was Eli Lilly and Company's net income before $20.64 billion? $10.59 billion, valid from December 31, 2024 to December 31, 2025 (status superseded), from a primary source (sec.gov). ## Read on - This page: /record/eli-lilly/net_income (markdown: /record/eli-lilly/net_income.md) - Entity twin: /record/eli-lilly.md ยท timeline: /timelines/eli-lilly.md - Every company's net income: /facts/net_income.md --- AsOf is a temporal fact ledger: a structured, dated, sourced record of what is true and what changed, built for AI retrieval.